Loreta is an aromatase inhibitor indicated for:
-- Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
-- Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy.
-- First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer.
Dosage & Administration
Loreta tablets are taken orally without regard to meals.
Recommended dose: 2.5 mg once daily.
Use of Letrozole may cause decreases in bone mineral density (BMD). Consideration should be given to monitoring BMD. Updated results from the BMD sub-study demonstrated that at 2 years patients receiving Loreta had a median decrease from baseline of 3.8% in hip BMD compared to a median decrease of 2.0% in the placebo group. The changes from baseline in lumbar spine BMD in Loreta and placebo treated groups were not statistically different.